Capstone Therapeutics Corporation expects to establish a positive corporate EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The company anticipates that the material impact of recent cost reductions will begin to show in the first quarter and become clear in the quarter ending June 30, 2026. In Q1 2026, Capstone plans to release an earnings power presentation outlining a range of EBITDA expectations under various macroeconomic scenarios. The company is making steady progress toward achieving 10% EBITDA margins and durable, profitable growth, supported by operating leverage, organic growth, and a focus on high-margin products and services. In 2025, Capstone scaled to $70 million in pro forma revenue and improved its year-over-year gross margin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1132907) on February 03, 2026, and is solely responsible for the information contained therein.